Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Dec 17, 2023 8:31pm
169 Views
Post# 35789099

RE:RE:RE:RE:RE:Good Comments, Engcan.

RE:RE:RE:RE:RE:Good Comments, Engcan.Not sure this is quite accurate.

I have verified from a few reliable contacts that Geraldine and her science is very highly respected in cosmetics valley. One person's words "a rockstar". Sirona was lucky to acquire the capability.

My assessment over the years is that Howard is the one raising the capital to bring the various pipelines to different stages of maturity.

We have seen the company go from preclinical license strategy all the way through to what could be ultimately an end to end solution to the customer, TBD.

If they hadn't of taken a see and wait approach for so long, we would have been filthy rich long time ago.


<< Previous
Bullboard Posts
Next >>